Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Christine Mehner, Ann L Oberg, Kimberly R. Kalli, Aziza Nassar, Alexandra Hockla, Devon Pendlebury, Magdalena A. Cichon, Krista M. Goergen, Matthew J. Maurer, Ellen L Goode, Gary Keeney, Aminah Jatoi, Miklós Sahin-Tóth, John A III Copland, Derek C Radisky, Evette S Radisky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.

Original languageEnglish (US)
Pages (from-to)35737-35754
Number of pages18
JournalOncotarget
Volume6
Issue number34
DOIs
StatePublished - 2015

Fingerprint

Anoikis
Serine Proteinase Inhibitors
Ovarian Neoplasms
Neoplasms
Epidermal Growth Factor Receptor
Peptide Hydrolases
Survival Rate
Cell Proliferation
Survival
Therapeutics

Keywords

  • Anoikis
  • EGFR
  • Ovarian cancer
  • Serine protease inhibitor
  • SPINK1

ASJC Scopus subject areas

  • Oncology

Cite this

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. / Mehner, Christine; Oberg, Ann L; Kalli, Kimberly R.; Nassar, Aziza; Hockla, Alexandra; Pendlebury, Devon; Cichon, Magdalena A.; Goergen, Krista M.; Maurer, Matthew J.; Goode, Ellen L; Keeney, Gary; Jatoi, Aminah; Sahin-Tóth, Miklós; Copland, John A III; Radisky, Derek C; Radisky, Evette S.

In: Oncotarget, Vol. 6, No. 34, 2015, p. 35737-35754.

Research output: Contribution to journalArticle

Mehner, Christine ; Oberg, Ann L ; Kalli, Kimberly R. ; Nassar, Aziza ; Hockla, Alexandra ; Pendlebury, Devon ; Cichon, Magdalena A. ; Goergen, Krista M. ; Maurer, Matthew J. ; Goode, Ellen L ; Keeney, Gary ; Jatoi, Aminah ; Sahin-Tóth, Miklós ; Copland, John A III ; Radisky, Derek C ; Radisky, Evette S. / Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. In: Oncotarget. 2015 ; Vol. 6, No. 34. pp. 35737-35754.
@article{366f8797859a4f9cbf2af97b4c845604,
title = "Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers",
abstract = "Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.",
keywords = "Anoikis, EGFR, Ovarian cancer, Serine protease inhibitor, SPINK1",
author = "Christine Mehner and Oberg, {Ann L} and Kalli, {Kimberly R.} and Aziza Nassar and Alexandra Hockla and Devon Pendlebury and Cichon, {Magdalena A.} and Goergen, {Krista M.} and Maurer, {Matthew J.} and Goode, {Ellen L} and Gary Keeney and Aminah Jatoi and Mikl{\'o}s Sahin-T{\'o}th and Copland, {John A III} and Radisky, {Derek C} and Radisky, {Evette S}",
year = "2015",
doi = "10.18632/oncotarget.5927",
language = "English (US)",
volume = "6",
pages = "35737--35754",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "34",

}

TY - JOUR

T1 - Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

AU - Mehner, Christine

AU - Oberg, Ann L

AU - Kalli, Kimberly R.

AU - Nassar, Aziza

AU - Hockla, Alexandra

AU - Pendlebury, Devon

AU - Cichon, Magdalena A.

AU - Goergen, Krista M.

AU - Maurer, Matthew J.

AU - Goode, Ellen L

AU - Keeney, Gary

AU - Jatoi, Aminah

AU - Sahin-Tóth, Miklós

AU - Copland, John A III

AU - Radisky, Derek C

AU - Radisky, Evette S

PY - 2015

Y1 - 2015

N2 - Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.

AB - Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.

KW - Anoikis

KW - EGFR

KW - Ovarian cancer

KW - Serine protease inhibitor

KW - SPINK1

UR - http://www.scopus.com/inward/record.url?scp=84946865860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946865860&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5927

DO - 10.18632/oncotarget.5927

M3 - Article

VL - 6

SP - 35737

EP - 35754

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -